Pediatr Gastroenterol Nutr. 2020 May 12.doi: 10.1097/MPG.0000000000002785.Online ahead of print.

Samit Patel ¹, Puanani Hopson ¹, Jeffrey Bornstein ², Shaista Safder ³

Author information

¹Pediatric Gastroenterology Fellow, Center for Digestive Health and Nutrition, Arnold Palmer Hospital for Children, Orlando, FL.

²Clinical Assistant Professor of Pediatric Gastroenterology, The Florida State University, Assistant Professor of Pediatrics, UCF College of Medicine, Center for Digestive Health and Nutrition, Arnold Palmer Hospital for Children, Orlando, FL.

³Clinical Assistant Professor of Pediatrics, The Florida State University, Assistant Professor of Pediatrics, UCF College of Medicine, Center for Digestive Health and Nutrition, Arnold Palmer Hospital for Children, Orlando, FL.

Abstract

Introduction: Children with fecal incontinence and constipation can be classified into three groups: neurogenic bowel dysfunction related to spinal cord defects (NBD), refractory constipation (RC), or anorectal malformations (ARM). The transanal irrigation (TAI) device (Peristeen®) was approved in 2012 by the FDA. This system uses a pump rather than gravity to instill water as a colonic irrigant and utilizes balloon occlusion of the rectum. Our aim was to evaluate the effectiveness of TAI (Peristeen®) in children who failed to respond to conservative measures for stool incontinence and constipation.

Methods: Retrospective study of 147 patients prescribed TAI between January 2014 and January 2020. Data collected included demographics, prior bowel regimen, symptoms before and after, patient satisfaction scores, and neurogenic bowel dysfunction scores.

Results: Of the 147 patients initiated, 114 remain active users (13 lost to follow up and 20 discontinued use). Multiple bowel regimens including laxatives (n = 139), cone enema (n = 40), and cecostomy (n = 7) were tried previously. The majority of our patients (n = 85) have NBD, primarily spina bifida, followed by RC (n = 43), and ARM (n = 19). For all patient groups, there was significant improvement in symptoms of fecal incontinence and constipation (p ≤ 0.001). Abdominal pain was improved in the NBD and RC group, but not significantly in the ARM group.

Conclusions: We provide a single-center review of a large pediatric cohort using TAI (Peristeen®) for management of fecal incontinence and constipation. Peristeen® offered significant improvement in patients with NBD, RC, and ARM.